Take­da touts in­ter­im PhI­II da­ta of en­zyme re­place­ment ther­a­py for rare blood dis­ease

Take­da says in an in­ter­im Phase III analy­sis that its en­zyme re­place­ment ther­a­py re­duced in­stances of low blood platelet count for pa­tients with a rare blood clot dis­or­der known as con­gen­i­tal throm­bot­ic throm­bo­cy­topenic pur­pu­ra (cTTP) com­pared to stan­dard of care plas­ma-based ther­a­pies.

Next, it plans to file for au­tho­riza­tion for the drug lat­er this year “broad­ly — so not just in the US and EMA but al­so oth­er ju­ris­dic­tions glob­al­ly,” Take­da head of rare ge­net­ics and hema­tol­ogy Dan Cur­ran told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.